ArticleWorld journal of gastrointestinal oncology2025
Rectal neuroendocrine tumors in a Latin American population: Insights from a Peruvian national cancer institute.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWell-differentiated rectal neuroendocrine tumors (rNETs) represent approximately 28% of gastrointestinal neuroendocrine tumors, with a rising incidence over recent decades. However, data from Perú remains limited.
aimTo assess overall survival (OS) in patients with rNETs and describe the clinical and pathological characteristics of the study population.
methodsThis retrospective study included patients diagnosed with rNETs at the Instituto Nacional de Enfermedades Neoplásicas between 2009 and 2024. Qualitative variables were evaluated using the
resultsA total of 52 patients were included, with a mean age of 51.9 years (range: 27-74 years) and composed of 65.4% females. The most common stage at diagnosis was stage I (48.1%), followed by stage IV (36.5%). The median OS within the study population was 76 months. The 5-year OS for grade 1 tumors was 92.9% compared to 32.6% for grade 2 tumors (
conclusionrNETs exceeding 2 cm in size, classified as grade 2, or presenting with lymph node involvement 1 status were correlated with advanced disease stages and diminished survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.